Atossa Genetics Inc. Stock

$0.88

0.24% yesterday

Nasdaq, Jun 27, 10:06 pm CET

ISIN

US04962H5063

Symbol

ATOS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Atossa Genetics Inc. Stock price

$0.88

-3.05 77.62% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.00 0.24%

ISIN

US04962H5063

Symbol

ATOS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Basic

Market capitalization

$113.6m

Enterprise Value

$48.5m

Net debt

$-65.1m

Cash

$65.1m

Shares outstanding

129.2m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

negative

P/B

1.74

Financial Health

Equity Ratio

93.50%

Return on Equity

-35.68%

ROCE

-45.57%

ROIC

-1,012.41%

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-29.8m | -

EBIT

$-29.8m

Net Income

$-26.3m | $-32.9m

Free Cash Flow

$-22.3m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

13.06% | -

EBIT

13.09%

Net Income

11.28% | -29.18%

Free Cash Flow

-19.69%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-0.21

FCF per Share

$-0.17

Short interest

5.74%

Employees

15.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Atossa Genetics Inc. Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Atossa Genetics Inc. forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Atossa Genetics Inc. forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Atossa Genetics Inc.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	14 14	1% 1% -
- Research and Development Expense	15 15	17% 17% -
EBITDA	-30 -30	13% 13% -
- Depreciation and Amortization	0.02 0.02	33% 33% -
EBIT (Operating Income) EBIT	-30 -30	13% 13% -
Net Profit	-26 -26	11% 11% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Atossa Genetics Inc. Stock News

Neutral

PRNewsWire

●

26 days ago

Atossa Therapeutics to Present at the Jefferies Global Healthcare Conference

SEATTLE , June 2, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that Dr. Steven Quay, M.D., Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 7:35 a.m.

Neutral

Accesswire

●

about one month ago

Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22

SEATTLE, WASHINGTON / ACCESS Newswire / May 20, 2025 / Atossa Therapeutics, Inc. (Nasdaq:ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, is pleased to invite investors to a webinar on May 22, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Dr. Steven Quay, CEO of Atossa Therape...

Neutral

PRNewsWire

●

about 2 months ago

Atossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑Endoxifen

Feasibility endpoint achieved; rapid Ki‑67 suppression and substantial MRI‑confirmed tumor shrinkage observed with favorable safety profile SEATTLE , May 14, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today reported full results from the Phase 2 Endocrine...

More Atossa Genetics Inc. News

Company Profile

Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

Head office	United States
CEO	Steven Quay
Employees	15
Founded	2008
Website	atossatherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now